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Abstract
The mitogen-activated protein kinase (MAP kinase) signalling cascade activated by fibroblast growth factors (FGF1 and
FGF2) was analysed in a model system, Xenopus oocytes, expressing fibroblast growth factor receptors (FGFR1 and
FGFR4). Stimulation of FGFR1 by FGF1 or FGF2 and FGFR4 by FGF1 induced a sustained phosphorylation of
extracellular signal-regulated protein kinase 2 (ERK2) and meiosis reinitiation. In contrast, FGFR4 stimulation by FGF2
induced an early transient activation of ERK2 and no meiosis reinitiation. FGFR4 transduction cascades were differently
activated by FGF1 and FGF2. Early phosphorylation of ERK2 was blocked by the dominant negative form of growth
factor-bound protein 2 (Grb2) and Ras, for FGF1^FGFR4 and FGF2^FGFR4. The phosphatidylinositol 3-kinase (PI3
kinase) inhibitors wortmannin and LY294002 only prevented the early ERK2 phosphorylation triggered by FGF2^FGFR4
but not by FGF1^FGFR4. ERK2 phosphorylation triggered by FGFR4 depended on the Grb2/Ras pathway and also
involved PI3 kinase in a time-dependent manner. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Fibroblast growth factors (FGFs) display pleiotro-
pic e¡ects on various cell types, ranging from the
di¡erentiation of embryonic cells to pathological re-
sponses in cancer cells [1]. Their responses are trig-
gered by the activation of structurally related trans-
membrane tyrosine kinase receptors (FGFRs)
encompassing four identi¢ed members and their al-
ternative splice variants [2]. Under ligand stimula-
tion, FGFRs elicit a speci¢c pattern of signal trans-
duction pathways including the activation of
molecular e¡ectors from Ras-dependent and Ras-in-
dependent pathways [3]. Molecular e¡ectors from the
Ras pathway include Shc and FRS2 which interact
with growth factor-bound protein 2 (Grb2) adapter
protein to activate the Ras/mitogen-activated protein
(MAP) kinase pathway allowing cell mitosis to oc-
cur. Likewise, the recruitment of the phospholipase
CQ (PLCQ) enzyme and the cytoplasmic tyrosine ki-
nase Src from the Ras-independent pathway gener-
ates transduction cascades involved in various cell
processes. A higher degree of complexity in FGFR
signalling is brought about by the possible combina-
torial interaction between a speci¢c FGF and one of
the four FGFRs. It appears that each interaction
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between FGFR and FGF displays speci¢c binding
properties. The molecular e¡ectors activated by the
di¡erent FGFR^FGF interactions seem to be the
same, but their degree of activity varies after ligand
binding as reported for FGF2 action on FGFR1 and
FGFR4 [4,5]. Also it is questioned whether the level
of activation of molecular e¡ectors changes for the
di¡erent FGF^FGFR interactions and whether it
can control some cell processes.
In order to better approach the characteristics of
the transduction cascades initiated by FGFRs, we
have used Xenopus laevis oocytes as a model system.
These germinal cells are naturally arrested at the G2^
M border of the ¢rst meiotic division. Stimulation of
their endogenous insulin-like growth factor 1 recep-
tor (IGF1R) [6] or of expressed tyrosine kinase re-
ceptors [7^9] activates transduction cascade e¡ectors,
such as Grb2/Ras, phosphatidylinositol 3-kinase (PI3
kinase), and extracellular signal-regulated protein ki-
nase 2 (ERK2), and leads to a meiosis reinitiation
characterised by germinal vesicle breakdown
(GVBD). Xenopus oocytes do not express FGFR or
FGF and represent a suitable system to analyse
transduction cascades activated by a given combina-
torial interaction between FGFR and FGF. In this
study, FGFR1 and FGFR4 from Pleurodeles, iden-
ti¢ed as homologous to human receptors, are ex-
pressed in Xenopus immature oocytes. Oocyte
GVBD is used to sort out the signalling cascades
triggered by FGFR1 and FGFR4. The involvement
of the Ras/MAP kinase pathway and of PI3 kinase is
analysed for FGFR4 under FGF1 and FGF2 stim-
ulation.
2. Materials and methods
2.1. Oocyte handling
Adult unprimed X. laevis females were purchased
from CNRS, Rennes, France. After anaesthesia with
MS 222 (1 g/l, Sandoz), ovarian lobes were surgically
removed and placed in ND96 medium (in mM: NaCl
96, KCl 2, CaCl2 1.8, MgCl2 1, HEPES 5, adjusted
to pH 7.4 with NaOH), supplemented with strepto-
mycin/penicillin (50 Wg/ml, Eurobio), sodium pyru-
vate (225 Wg/ml, Sigma) and soybean trypsin inhib-
itor (30 Wg/ml, Sigma) [10,11]. Full-grown stage VI
X. laevis oocytes were obtained by defolliculation
using a 1 h treatment with collagenase A (1 mg/ml,
Boehringer Mannheim). Complete defolliculation of
the oocytes was achieved by manual dissection. Oo-
cytes were then kept at 19‡C in ND96 medium.
2.2. cRNA preparation
Capped cRNAs were transcribed using the mMES-
SAGE mMACHINE kit (Ambion). The cRNAs
were linearised from full-length cDNAs inserted
into vector pSP64T, including Pleurodeles FGFR1
and FGFR4 cDNAs, chimeric PDGFR^FGFR1
and PDGFR^FGFR4 cDNAs, EGFR cDNA, mu-
tated Grb2 cDNA (Grb2-P49L), and a dominant
negative form of oncogenic Ras cDNA (Rasdn)
[12,13].
2.3. Microinjection and drug treatments of oocytes
Microinjection was performed in the equatorial
region of the oocyte with the cRNAs (60 ng). Stim-
ulation by growth factors (FGF1, FGF2, EGF,
PDGF-BB, 5 nM) was performed on 48 h expressing
oocytes. The mutated Grb2 or Ras cRNA was in-
jected 24 h after FGFR cRNA injections, at a con-
centration 10 times higher.
Drugs (wortmannin, 50 nM, and LY294002, 20
WM [14], or genistein, 10 WM, Sigma) were added
2 h before the addition of FGF to the extracellular
medium and maintained during the course of the
experiment. Controls were performed either with ad-
dition of progesterone (2 Wg/ml), on uninjected oo-
cytes or on water-injected oocytes.
2.4. Analysis of GVBD
Each experiment is the mean of batches of 30 oo-
cytes that originated from n animals (n = number of
animals utilised). Fifteen hours after FGF addition,
oocytes were ¢xed in Smith’s ¢xative overnight and
embedded in para⁄n for serial sections. Student’s
t-test was used to assess the signi¢cance of the ob-
served di¡erences.
2.5. Electrophoresis and Western blot analysis
For ERK2 phosphorylation, oocytes were homo-
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genised at 4‡C [15]. Electrophoresis was run on a
15% modi¢ed polyacrylamide gel. For FGFR4 phos-
phorylation, oocytes were homogenised in lysis bu¡-
er added with 1% Triton X-100. Electrophoresis was
run on a 7.5% modi¢ed polyacrylamide gel. Western
blottings were realised onto Hybond ECL membrane
(Amersham life Sciences) in TBS pH 8 (mM: Tris^
HCl 15, NaCl 150, Tween 0.1%, containing 10% bo-
vine serum albumin, Sigma) with an ERK2 antibody
(1/3000, 1 h, Santa Cruz Biotechnology) or with an
anti-phosphotyrosine antibody (1/1000, overnight at
4‡C, Transduction Laboratory).
3. Results and discussion
In this study, we used Xenopus oocyte meiotic mat-
uration (GVBD) to distinguish the e¡ects of FGFR1
and FGFR4 activation by FGF1 and FGF2. GVBD
occurred for FGFR1 activated by FGF1
(85.2 þ 14.9%, n = 14) as previously described [9] but
also for FGFR1 stimulated by FGF2 (87.1 þ 10.2%,
n = 4) and for FGFR4 under FGF1 addition
(74.1 þ 24.3%, n = 8). The reinitiation of the oocyte
G2 phase occurs 15 h after ligand addition. This
time is approximately identical for IGF1R [16] but
longer for the natural hormonal inducer progester-
one [17]. In contrast, FGF2 addition on FGFR4 did
not induce a signi¢cant percentage of GVBD
(9.3 þ 19.8, n = 8). Controls performed on oocytes ex-
pressing EGFR and on progesterone-treated oocytes
showed a high percentage of GVBD (respectively
85 þ 23.8, n = 4, and 96.5 þ 8.5, n = 12) (Fig. 1).
It further appears that the lack of e¡ect of FGF2
in oocytes expressing FGFR4 did not result from a
defect of FGFR4 activation. By Western blot analy-
sis, we detected tyrosine phosphorylation of FGFR4
5 min after FGF1 or FGF2 addition, whereas no
phosphorylation was detected in unstimulated oo-
cytes (Fig. 2). Moreover, we previously demon-
strated, using electrophysiological techniques, that
FGF1 and FGF2 activate calcium oscillations in a
PLCQ-dependent manner in FGFR4 as in oocytes
expressing FGFR1 [10,11]. These results clearly
show that FGFR4 transactivation occurred under
both FGF1 and FGF2 addition.
FGFR1 and FGFR4 share close binding proper-
ties for FGFs [4] but only FGFR1 displays a mito-
genic e¡ect on some somatic cells [4,5]. The di¡er-
ential GVBD results obtained for FGF1 and FGF2
in oocytes expressing FGFR4 made us analyse
whether FGFR4 requires intracellular and/or extra-
cellular domains to display a di¡erential e¡ect. Chi-
mera receptors composed of the extracellular domain
of the PDGFR coupled with the human FGFR1 or
FGFR4 intracellular domain were expressed and
stimulated with PDGF-BB (5 nM). No di¡erences
were obtained between FGFR1 stimulated with
FGF1 or FGF2 and PDGFR^FGFR1 activated by
PDGF-BB (58.1 þ 9.8%, n = 4) nor between FGF1^
FGFR4 interaction and PDGFR^FGFR4 activated
by PDGF-BB (83.2 þ 17.9%, n = 8) (Fig. 1). These
results demonstrate that the intracellular domain of
FGFR1 or FGFR4 responds to a ligand-induced au-
tophosphorylation signal and triggers GVBD. They
Fig. 1. Percentage of GVBD in oocytes expressing FGFR1,
FGFR4, EGFR or PDGFR^FGFR1 and PDGFR^FGFR4 for
48 h and treated respectively with FGF1, FGF2, EGF or
PDGF-BB (5 nM). Controls were realised with addition of pro-
gesterone (PG), the natural hormonal inducer (2 Wg/ml).
Fig. 2. Western blot analysis of tyrosine phosphorylation of
FGFR4 (arrow), expressed for 48 h in oocytes, left unstimulat-
ed (0) or treated for 5 min with FGF1 or FGF2 (5 nM).
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also point toward the major role played by the
FGFR4 extracellular domain in the di¡erent re-
sponses to various FGF ligands that generate a
GVBD response under FGF1 activation but not
under FGF2 addition. FGFR extracellular domains
control transduction pathways initiated by FGFR in
some cell types [18]. Some reports mentioned the
function of membranous or extracellular matrix hep-
aran sulfate proteoglycans (HSPG) as binders and
modulators of FGFs [18^20]. HSPG can discriminate
between FGF1 and FGF2 action on FGFR4 in liver
parenchymal cells [21]. However, FGF2 remains un-
able to trigger a GVBD in oocytes expressing
FGFR4 after addition of 10 mM heparin. Thus it
seems more likely that the FGFR4 extracellular do-
main and/or the conformational di¡erences between
FGF1 and FGF2 allow a di¡erential signalling in the
oocyte model system.
In Xenopus oocytes ERK2 phosphorylation corre-
lates with GVBD [6,22^26]. During oocyte matura-
tion the MAP kinase cascade is activated in an ultra-
sensitive fashion [27]. Reports have mentioned that
di¡erential activation of MAP kinase controls cell
growth and di¡erentiation in somatic cells [28,29].
A di¡erential activation of ERK2 in oocytes could
correlate with the diverse e¡ects obtained for di¡er-
ent FGFR^FGF interactions. As seen in Fig. 3B, a
shift to a higher molecular weight, after 15 h of
growth factor action, demonstrates the phosphoryla-
tion of ERK2 for FGFR1 under FGF1 and FGF2
action and FGFR4 under FGF1 stimulation. Con-
trols performed with EGF addition on oocytes ex-
pressing EGFR or with oocytes treated with the nat-
ural inducer progesterone also showed a
phosphorylation of ERK2. After respectively 15
min and 3 h unphosphorylated and phosphorylated
forms of ERK2 are present in oocytes expressing
FGFR1 under FGF1 and FGF2 addition as well
as in oocytes expressing EGFR under EGF action
(Fig. 3A). In contrast, FGF1 or FGF2 action on
FGFR4 induces a di¡erent pattern of ERK2 phos-
phorylation. ERK2 phosphorylation was not de-
tected at 15 min but at 3 h for FGF1^FGFR4 and
FGF2^FGFR4 interactions (Fig. 3A). Moreover, the
phosphorylation of ERK2 induced by FGF2^
FGFR4 was transient. Our results are in agreement
with previous reports mentioning a di¡erential acti-
vation of MAP kinase between FGFR1 and FGFR4
under FGF2 addition where FGFR4 produces a low-
er stimulation of MAP kinase [4,30,31].
We further estimated the di¡erential responsive-
ness of Xenopus oocytes expressing FGFR4 under
FGF1 and FGF2 stimulation by the dissection of
two signalling cascades. The use of genistein, an in-
hibitor of protein tyrosine kinase, prevented the
Fig. 4. Percentage of GVBD observed in oocytes expressing
FGFR4, treated for 15 h with FGF1 (5 nM) (C). The mutated
Grb2 (Grb2dn) and Ras (Rasdn) cRNAs were injected 24 h be-
fore FGF1 addition. Genistein (G, 10 WM), wortmannin (W, 50
nM) and LY294002 (LY, 20 WM) were added 2 h before the
addition of FGF1 to the extracellular medium and maintained
during the course of the experiment.
Fig. 3. Western blot analysis of ERK2 from oocytes expressing
EGFR, FGFR1 (R1) and FGFR4 (R4) for 48 h, analysed 15
min and 3 h (A) or 15 h (B) after addition of EGF, FGF1 or
FGF2 (5 nM). Controls were performed with progesterone on
uninjected oocytes (PG) or on unstimulated oocytes (C). The
phosphorylated state of ERK2 is shown (P).
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FGF1^FGFR4-induced GVBD (Fig. 4) (0%, n = 2)
and FGF1^FGFR4-induced ERK2 phosphorylation
(Fig. 5), showing the crucial role of tyrosine phos-
phorylation. The involvement of ERK2 upstream ef-
fectors was analysed using a dominant negative strat-
egy. Injection of dominant negative forms of Grb2
adapter or Ras protein inhibited the FGF1^FGFR4-
induced GVBD (respectively 5.6 þ 4.9%, n = 3 and
5 þ 7.8, n = 5) (Fig. 4) and ERK2 phosphorylation
(Fig. 5) at 3 and 15 h. The same inhibition was
obtained on early ERK2 phosphorylation induced
by FGF2^FGFR4 at 3 h (Fig. 5). In contrast, oo-
cytes expressing FGFR4 displayed a time-dependent
sensitivity to PI3 kinase inhibitors (wortmannin and
LY294002). Although GVBD and ERK2 phosphor-
ylation were inhibited by PI3 kinase inhibitors at 15
h for the FGF1^FGFR4 interaction, they exerted no
e¡ect on the early ERK2 phosphorylation state ob-
tained at 3 h (Fig. 5). In contrast, the early transient
phosphorylation induced by FGF2^FGFR4 at 3 h
was inhibited by PI3 kinase inhibitors. Progester-
one-induced GVBD and progesterone-induced
ERK2 phosphorylation were not altered in controls
performed on oocytes injected with Grb2dn or
Rasdn, 24 h prior to progesterone addition, or
treated with PI3 kinase inhibitors 2 h prior to pro-
gesterone stimulation. FGFR transduction pathways
activated in somatic cells clearly involve the Grb2
adapter [32] while the function of PI3 kinase is less
de¢ned. PI3 kinase was associated with neurite out-
growth [33,34] but was reported to be dispensable for
other cell functions induced by FGFs. Our results
show that the activation of the Grb2/Ras pathway
and a late recruitment of PI3 kinase are needed to
trigger GVBD and sustained ERK2 phosphoryla-
tion. In oocytes expressing FGFR4 a di¡erential sen-
sitivity of early ERK2 phosphorylation to PI3 kinase
inhibitors exists. PI3 kinase is involved in the early
signalling of FGFR4 under FGF2 treatment, while it
is only required for a late e¡ect of FGF1.
In conclusion, a di¡erential phosphorylation of
ERK2 exists between FGFR1 and FGFR4 under
FGF1 and FGF2 action. ERK2 phosphorylation in-
duced by FGFR4 correlates with a time-dependent
recruitment of PI3 kinase. These results emphasise
the use of Xenopus oocytes as a model system to
dissect the interaction between the PI3 kinase and
the MAP kinase transduction cascades activated by
a given set of FGF^FGFRs with the hypothesis that
each combinatorial activation of ligand^receptor is
optimally adapted to respond with a repertoire of
distinct levels of intracellular transduction signals.
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